PDS BIOTECHNOLOGY CORP (PDSB) Stock News

USA - NASDAQ:PDSB - US70465T1079 - Common Stock

0.9558 USD

+0.01 (+0.9%)

Last: 10/13/2025, 8:00:00 PM

0.97 USD

+0.01 (+1.49%)

After Hours: 10/13/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PDSB Latest News, Press Relases and Analysis

All

Press Releases

26 days ago - By: PDS Biotechnology Corporation

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

2 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

2 months ago - By: The Motley Fool

PDSB Loss Improves as Costs Drop

2 months ago - By: Benzinga

Insights into PDS Biotechnology's Upcoming Earnings

5 months ago - By: Benzinga

Insights Ahead: PDS Biotechnology's Quarterly Earnings

2 months ago - By: PDS Biotechnology Corporation

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

2 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

4 months ago - By: PDS Biotechnology Corporation

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

4 months ago - By: Zacks Investment Research - Mentions: INTU ADP PWR FAST ...

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

4 months ago - By: PDS Biotechnology Corporation

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

5 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

5 months ago - By: Yahoo Finance - Mentions: IBRX COMM HD CAVA ...

Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT

5 months ago - By: PDS Biotechnology Corporation

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

5 months ago - By: PDS Biotechnology Corporation

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

5 months ago - By: PDS Biotechnology Corporation

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

6 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

6 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

7 months ago - By: Stocktwits - Mentions: VTI VXF

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish

7 months ago - By: PDS Biotechnology Corporation

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

7 months ago - By: PDS Biotechnology Corporation

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

7 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

7 months ago - By: Virtual Investor Conferences - Mentions: CGTX AVCN.CA COCP NGEN.CA ...

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

7 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

7 months ago - By: Virtual Investor Conferences - Mentions: CGTX AVCN.CA COCP NGEN.CA ...

Life Sciences Investor Forum Agenda Announced for March 13th

7 months ago - By: PDS Biotechnology Corporation

PDS Biotech Leadership to Participate in March Conferences

7 months ago - By: PDS Biotechnology Corporation

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

8 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

8 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

8 months ago - By: PDS Biotechnology Corporation

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

10 months ago - By: PDS Biotechnology Corporation

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)